Clinical trial
The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate…
NCT00295750 · Ferring Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00295750 |
|---|---|
| Title | The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer |
| Official title | An Open-label, Multi-Centre, Randomized, Parallel-group Study, Investigating the Efficacy and Safety of Degarelix One Month Dosing Regimens; 160 mg (40 mg/ml) and 80 mg (20mg/ml), in Comparison to LUPRON DEPOT® 7.5 mg in Patients With Prostate Cancer Requiring Androgen Ablation Therapy |
| Lead sponsor | Ferring Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Degarelix, Leuprolide 7.5 mg |
| Enrollment | 620 |
| Start date | Feb 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Feb 24, 2006 |
| Last update posted | Dec 19, 2012 |
| Countries | Canada, Czechia, Germany, Hungary, Mexico, Netherlands, Puerto Rico, Romania, Russia, Ukraine, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: